Alchemab launches Phase 1 trial for ATLX-1282, secures extra $32M funding

Alchemab Therapeutics today announced that it has initiated a Phase 1 first-in-human study of its antibody therapy ATLX-1282, licensed to Eli Lilly and Company in May 2025. According to the company, Lilly will lead later development and commercialization of ATLX-1282, while Alchemab conducts the ini…